FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antagonist topics
Antagonist
Recurrence
Proliferative Disorder
Proliferative
Antibodies
Progesterone
Dicyclomine
Scopolamine
Extracellular
Pharmaceutically Acceptable Salt
Metalloprotein
Nucleic Acids
Polynucleotide
Nucleic Acid
Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antagonist patents



      
           
This page is updated frequently with new Antagonist-related patent applications. Subscribe to the Antagonist RSS feed to automatically get the update: related Antagonist RSS feeds. RSS updates for this page: Antagonist RSS RSS


Date/App# patent app List of recent Antagonist-related patents
07/24/14
20140206876
 2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists patent thumbnailnew patent 2-(substituted ethynyl)quinoline derivatives as mglur5 antagonists
Provided is a 2-(substituted ethynyl)quinoline derivative having an mglur5 antagonistic activity and pharmaceutically acceptable salts thereof. The compound of the present invention can be useful as a medicament for treating and preventing mglur5 receptor-mediated diseases such as alzheimer's disease, senile dementia, parkinson's disease, l-dopa-induced dyskinesia, huntington's chorea, amyotrophic lateral sclerosis, multiple sclerosis, schizophrenia, anxiety disorder, depression, neuropathic pain, drug dependence, fragile x syndrome, autism, migraine and gastroesophageal reflux disease (gerd)..
07/24/14
20140206836
 Novel n- and c-terminal substituted antagonistic analogs of gh-rh patent thumbnailnew patent Novel n- and c-terminal substituted antagonistic analogs of gh-rh
There is provided a novel series of synthetic analogs of hgh-rh(1-29)nh2 (seq id no: 1) and hgh-rh(1-30)nh2. Of particular interest are those carrying phac, n-me-aib, dca, ac-ada, fer, ac-amc, me-nh-sub, phac-ada, ac-ada-d-phe, ac-ada-phe, dca-ada, dca-amc, nac-ada, ada-ada, or ch3—(ch2)10—co-ada, at the n-terminus and β-ala, amc, apa, ada, ae2a, ae4p, ε-lys(α-nh2), agm, lys(oct) or ahx, at the c-terminus.
07/24/14
20140206722
 Methods of use of phenoxypropylamine compounds to treat depression patent thumbnailnew patent Methods of use of phenoxypropylamine compounds to treat depression
Disclosed herein are compositions and methods for treating depression using compositions comprising a compound of formula i. Disclosed herein are compositions and methods for treating depression using compositions comprising phenoxypropylamine compounds and derivatives having selective affinity for and antagonistic activity against the 5-ht1a receptor, as well as 5-ht reuptake inhibitory activity.
07/24/14
20140205675
 Horse feed dietary supplement composition derived from chia seed composition patent thumbnailnew patent Horse feed dietary supplement composition derived from chia seed composition
A horse feed dietary supplement composition increases the energy and improves the health and coat of a horse and is formed as a partially defatted seed meal composition that may be supplemented to a horse feed. The composition includes a shelf stable, partially defatted supercritical co2 fluid solvent extracted whole grain flour that is derived from salvia hispanica l.
07/24/14
20140205608
 Use of c-fms antagonists patent thumbnailnew patent Use of c-fms antagonists
The present invention relates generally to a method for the treatment and/or prophylaxis of osteoarthritis (oa) and/or pain. In accordance with the present invention, an antagonist of c-fms is effective in the treatment of osteoarthritis and/or pain.
07/24/14
20140205606
 Anti c-met antibodies patent thumbnailnew patent Anti c-met antibodies
The present invention relates to antibodies that specifically bind to the human c-met receptor protein and that act as strict antagonists of hepatocyte growth factor (hgf)-mediated activation of the c-met receptor and also inhibit hgf-independent activation of the human c-met protein.. .
07/24/14
20140205602
 Antagonist anti-cd40 monoclonal antibodies and methods for their use patent thumbnailnew patent Antagonist anti-cd40 monoclonal antibodies and methods for their use
Compositions and methods of therapy for treating diseases mediated by stimulation of cd40 signaling on cd40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-cd40 antibody or antigen-binding fragment thereof to a patient in need thereof.
07/24/14
20140205600
 Methods of promoting fat loss comprising administering an alk7 inhibitor patent thumbnailnew patent Methods of promoting fat loss comprising administering an alk7 inhibitor
The invention relates to alk7 soluble receptors and their uses as antagonists of the function of certain ligands such as gdf-8 (myostatin) and gdf-11. The alk7 soluble receptor of the invention is useful as antagonists of gdf-8 and gdf-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases.
07/24/14
20140205596
 Organic compounds patent thumbnailnew patent Organic compounds
The invention relates to compounds and methods of treatment relating to nicotinic receptor antagonists. For example, the compounds and methods of treatment function block the activity of certain acetylcholine receptors and subtypes therein, and are useful treating diseases and conditions mediated by nicotinic receptor stimulation, e.g., small cell lung cancer..
07/24/14
20140205595
 Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists patent thumbnailnew patent Compounds and methods of prophylaxis and treatment regarding nicotinic receptor antagonists
It is an object of the present invention that the novel nicotinic receptor antagonists disclosed herein may be used in a broad array of clinical or medicinal facets. For example, it is a contemplated use of the present invention that the novel nicotinic receptor antagonists be used to inhibit the growth cycle of non-small cell lung cancer cells.
07/17/14
20140200244
Phenylethanolamine-based nmda receptor antagonists
Wherein one or more of r1, r2, r3, r4, r5, or the ring formed by the joining of r1 and r2, is a hydrophobic moiety which confers enhanced antagonist activity as compared to existing nmda receptor antagonists, e.g., ifenprodil. Compounds described herein are designed based on the discovery that ifenprodil binds within the allosteric domain of the glun1/glun2b nmda receptor, particularly at the interface between glun1 and glun2b subunits.
07/17/14
20140200240
Methods for determining patient response to anti-platelet aggregation therapy
Diagnostic methods for determining whether an individual will benefit from a particular anti-thrombotic therapeutic agent are disclosed. The methods involve obtaining a biological sample that comprises platelets, from a patient who has been pre-administered a particular therapeutic agent, which is an antagonist of a receptor associated with the biochemical pathways involved in platelet aggregation, and exposing the platelets to an agonist of the receptor.
07/17/14
20140200236
Opioid agonist/antagonist combinations
The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome)..
07/17/14
20140200224
Benzenesulfonamide compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
The invention formula r1 is selected from the group consisting of hydrogen, linear c1-c3 alkyl and fluorinated linear c1-c3 alkyl; r2 is hydrogen or methyl; r is selected from the group consisting of hydrogen, halogen, c1-c2-alkyl, fluorinated c1-c2-alkyl, c1-c2-alkoxy and fluorinated c1-c2-alkoxy, r4 is c1-c2-alkyl or fluorinated c1-c2-alkyl; n is 0, 1 or 2, and the physiologically tolerated salts of these compounds and the n-oxides thereof. The invention also relates to a pharmaceutical composition that comprises at least one compound of the formula i and/or at least one physiologically tolerated acid addition salt thereof, and further to a method for treating disorders that respond beneficially to dopamine d3 receptor antagonists or dopamine d3 agonists, said method comprising administering an effective amount of at least one compound or physiologically tolerated acid addition salt of the formula i to a subject in need thereof..
07/17/14
20140200215
Lysophosphatidic acid receptor antagonists
Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.. .
07/17/14
20140200200
Antagonists of cb1 receptor
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
07/17/14
20140199399
Use of tgf-beta antagonists to treat infants at risk of developing bronchopulmonary dysplasia
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a tgf-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the tgf-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother..
07/17/14
20140199376
Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed..
07/17/14
20140199366
Sustained release intraocular implants and methods for treating ocular neuropathies
Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers.
07/17/14
20140199322
Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.. .
07/17/14
20140199315
Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (negative regulator). Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
07/17/14
20140199299
Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target cd3 on t cells and neutralize one or more biological activities of interleukin-6 (il-6), such as cd3 modulators including anti-cd3 antibodies and anti-il-6 antagonists including anti-il-6 antibodies, anti-il-6r antagonists including anti-il-6r antibodies, and/or anti-il-6/il-6r complex antagonists including anti-il-6/il-6r binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.. .
07/17/14
20140199237
Methods and compositions for modulation of olfml3 mediated angiogenesis
The present invention relates to antibodies against specific domains of olfml3 and the use of such in angiogenesis. In particular aspects, angiogenesis-related conditions, such as cancer, can be treated by the composition comprising the olfml3 antagonists..
07/10/14
20140194597
Modified chimeric polypeptides with improved pharmacokinetic properties
The present invention provides vegf antagonists with improved pharmacokinetic properties. According to certain embodiments, a fusion polypeptide capable of antagonizing vegf activity is provided comprising a modified extracellular ligand binding domain of a vegf receptor fused to a multimerizing component..
07/10/14
20140194517
Treatment of graft-versus-host disease disorders using rar antagonists
The present specification provides rar antagonist compounds, compositions comprising such rar antagonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such rar antagonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.. .
07/10/14
20140194515
Use of a composition comprising an antacid, a mucolytic and a gelling agent in the treatment of cold
The present invention is directed to a medicine to alleviate and cure colds by reducing acid content and stimulation of increased mucus production due to the fact that active components of the substance consist of acid stanching components like proton pumps stanches, histamine-2-receptor-antagonists, mucus stimulating components as acetylcysteine and alginic acid. This together creates an optimal healing environment in the respirator passages..
07/10/14
20140194514
Topical formulations
Topical treatments for neuropathy are described. The treatments include topical formulations of nmda antagonists and one additional active ingredient.
07/10/14
20140194456
Abuse-resistant controlled-release opioid dosage form
Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally.
07/10/14
20140194426
Dual-acting oxazole antihypertensive agents
Wherein: ar, z, r3, r4 and r5 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have at1 receptor antagonist activity and neprilysin inhibition activity.
07/10/14
20140193828
Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis.
07/10/14
20140193523
Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration
Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi-component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one nk-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug.
07/10/14
20140193465
Novel a4b7 peptide dimer antagonists
The invention relates to disulfide-rich dimer molecules which inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (madcam) in vivo, and show high selectivity against α4β1 binding.. .
07/10/14
20140193425
Treatment of cancer with alk1 antagonists
Methods for evaluating responsiveness of a subject having cancer to treatment with an activin receptor-like kinase 1 (alk1) antagonist are provided. Methods for selecting a subject for treatment with an alk1 antagonist based on the subject being identified as responsive to such treatment are also provided.
07/10/14
20140193419
Methods and compositions for treating and diagnosing diseases
Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (cat) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of cat, and methods for screening agents that modulate cat level or activity in vivo or in vitro..
07/10/14
20140193414
Anti-her antibodies
The invention provides anti-her antibodies, including multispecific anti-her antibodies, compositions comprising and methods of using these antibodies. Also provided herein are egfr/her3 multispecific antibodies that are less toxic than traditional egfr antagonists..
07/10/14
20140193397
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
The invention provides methods for identifying patient who may benefit from treatment with an anti-cancer therapy comprising a vegf antagonist. The invention also provides methods for monitoring a patients' response to the anti-cancer therapy.
07/10/14
20140193396
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
07/10/14
20140193376
Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment
The present embodiments provide for combinations of modulators that increase hematopoietic stem cell engraftment or increase mobilization in vivo. Methods and compositions for modulating the mobilization of stem cells, particularly for promoting or increasing the mobilization of hematopoietic stem cells (hscs) from the bone marrow to the peripheral blood are disclosed.
07/03/14
20140188013
Method and apparatus for applying neuromuscular electrical stimulation
A method and apparatus for applying neuromuscular electrical stimulation to an agonist/antagonist muscle pair to move a limb about a joint includes generating a first pattern of neuromuscular electrical stimulation pulses for output through a first channel to a first pair of electrodes and generating a second pattern of neuromuscular stimulation pulses for output through a second channel to a second pair of electrodes. The first pair of electrodes are attached to the agonist muscle of the agonist/antagonist muscle pair, and the second pair of electrodes are attached to the antagonist muscle.
07/03/14
20140187795
Crth2 modulators and preparation thereof
The present invention relates to processes and intermediates for the preparation of compounds useful as crth2 antagonists. Compounds prepared by the processes of the invention are of formula (ai), (all) and compound (i)..
07/03/14
20140187639
Small molecule antagonists of phosphatidylinositol-3,4,5-triphosphate (pip3) and uses thereof
Disclosed are new members of a class of non-lipid small molecule inhibitors which interfere with the interaction between phosphoinositol-3,4,5-triphosphate (pip3) and pleckstrin homology (ph) domains. These molecules target a broad range of pip3-dependent signaling events in vitro and exert significant anti-tumor activity in vivo, with improved activity and selectivity toward particular ph domains.
07/03/14
20140187585
5-ht2b receptor antagonists
The present invention relates to novel fluorinated piperidine derivatives having antagonistic activity at the 5-ht2b receptor, pharmaceutical compositions comprising these compounds and their use as a medicine.. .
07/03/14
20140187552
Method of treatment of aggression
The invention comprises a method of treatment of aggression and similar behavioral syndromes, such as impulsivity and irritability, by a pharmaceutical agent exhibiting combined d2 and d5 antagonistic activity.. .
07/03/14
20140187494
Inhibition of inflammation using antagonists of muc1
The invention provides for peptides from the muc1 cytoplasmic domain and methods of use therefor. These peptides can inhibit muc1 oligomerization, inhibit the interaction of muc1 with nf-κb or a stat, and block inflammatory response mediated by nf-κb or stat signaling..
07/03/14
20140187484
Na/k-atpase-derived peptide src inhibitors and ouabain antagonists and uses thereof
A novel src inhibitor that targets the na/k-atpase/src receptor complex and antagonizes ouabain-induced protein kinase cascades and uses thereof are disclosed.. .
07/03/14
20140186951
Novel opioid antagonists
Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.. .
07/03/14
20140186838
Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis.
07/03/14
20140186462
Anticoagulant antagonist and hemophilia procoagulant
A method for treating a coagulation deficient patient comprises administering an amount of polyp to the patient sufficient to reduce the pt test value or dilute pt test value of the plasma of the patient.. .
07/03/14
20140186374
Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
We demonstrate herein that neuritin controls the homeostasis of regulatory t cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory t cells in various disease settings is described.
07/03/14
20140186367
Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound..
07/03/14
20140186356
Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
The invention also relates to a composition comprising an antibody antagonist to c-met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use.
07/03/14
20140186346
Methods of treating pain using an il-31ra or osmr-b antagonist
Use of antagonists to il-31ra and osmrb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof.
06/26/14
20140179926
2,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous system diseases
Wherein x, z, r1-r4, and m are as defined in the claims, exhibit alpha2c antagonistic activity, and are thus useful as alpha2c antagonists. Methods for the treatment of diseases and conditions of the peripheric system and the central nervous system are also disclosed..
06/26/14
20140179907
Anti-cd40 antibodies
The present invention relates to new humanized antagonistic anti-cd40 antibodies and therapeutic and diagnostic methods and compositions for using the same.. .
06/26/14
20140179797
Composition for administering an nmda receptor antagonist to a subject
The invention provides extended release amantadine compositions for once daily administration of amantadine to a subject.. .
06/26/14
20140179750
Prostaglandin receptor ep2 antagonists, derivatives, compositions, and uses related thereto
The disclosure relates to prostaglandin receptor ep2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which ep2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflammation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof..
06/26/14
20140179734
Adhesive skin patch containing serotonin receptor antagonist drug
Provided is a transdermal absorption-type patch containing a serotonin receptor antagonist, which has a short transdermal absorption delay time (lag time), and in which the maximum transdermal permeation rate of the drug can be reached within a short time and the drug can disappear from circulating blood rapidly. That is, provided is a patch containing a serotonin receptor antagonist, wherein the patch contains an adhesive layer comprising a non-functional acrylic adhesive, a water-soluble organic amine, a fatty acid ester, and a serotonin receptor antagonist such as granisetron as an active ingredient..
06/26/14
20140179733
Diazole amides
Compounds are provided that act as potent antagonists of the ccr1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr1-mediated disease, and as controls in assays for the identification of competitive ccr1 antagonists..
06/26/14
20140179621
Methods for treating or preventing ophthalmological diseases
This invention relates to methods and compositions useful for the treatment or prevention of an ophthalmological disease, comprising administration of an effective amount of a pdgf antagonist and a vegf antagonist to a mammal in need thereof.. .
06/26/14
20140178403
Method of inhibiting binding or activity of mif by administering a mif antagonist
Methods and compositions for using the mhc class ii invariant chain polypeptide, ii (also known as cd74), as a receptor for macrophage migration inhibitory factor (mif), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of mif which bind to this receptor, or which otherwise modulate the interaction of mif with cd74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered mif levels, particularly inflammatory conditions and cancer..
06/26/14
20140178363
Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-vegf-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-vegf-specific antagonist.
06/26/14
20140178362
Methods and compositions for treating diseases targeting maba
Methods and compositions for detecting and treating a disease, particularly cancer, associated with differential expression of maba in disease cells compared to healthy cells. Also provided are antagonists or agonists of maba, and methods for screening agents that modulate the maba level or activity in vivo or in vitro..
06/19/14
20140171639
Trpm8 antagonists and their use in treatments
Where the definitions of the variables are provided herein.. .
06/19/14
20140171514
Nmda receptor antagonist formulation with reduced neurotoxicity
The present invention is directed to pharmaceutical compositions of effective amounts of nmda receptor antagonists and preservative for the administration to a patient in need of effective analgesia and anesthesia. The compositions of the invention advantageously do not cause any significant neurotoxicity.
06/19/14
20140171503
Nuclear receptor modulators and their use for the treatment and prevention of cancer
Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of formula i: wherein r1 to r5 and x1 to x5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed..
06/19/14
20140171480
Crystalline polymorphic forms of an antidiabetic compound
This compound is useful as a glucagon receptor antagonist and serves as a pharmaceutically active ingredient for the treatment of type 2 diabetes and related conditions, such as hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. Hydrates, hemihydrates, anhydrates and similar polymorphic forms are included..
06/19/14
20140171460
Methods and compositions for treatment of epithelial wounds
This invention relates to treatment of epithelial wounds. In particular, the invention relates to methods and formulations for treating epithelial wounds based on application of an opioid antagonist such as naltrexone..
06/19/14
20140171440
Methods of increasing liver proliferation
The present invention is directed to methods of enhancing liver repair after injury, resection or transplantation using antagonists of the bone morphogenetic protein (bmp) signaling pathway in the liver.. .
06/19/14
20140171436
Treatment of antifolate neurotoxicity
The present invention is a method of treating antifolate neurotoxicity in a mammal suffering from or at risk of developing antifolate neurotoxicity, which comprises administering to the mammal a therapeutically effective amount of an nmda antagonist, or a pharmaceutically acceptable salt thereof.. .
06/19/14
20140171420
Diazole lactams
Compounds are provided that act as potent antagonists of the ccr1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr1-mediated disease, and as controls in assays for the identification of competitive ccr1 antagonists..
06/19/14
20140171411
(thieno[2,3-b][1,5]benzoxazepin-4-yl)piperazin-1-yl compounds as dual activity h1 inverse agonists/5-ht2a antagonists
A dual h1 inverse agonist/5-ht2a receptor antagonist of the formula (i), its uses, and methods for its preparation are described.. .
06/19/14
20140171406
Trpm8 antagonists and their use in treatments
Where the definitions of the variables are provided herein.. .
06/19/14
20140171397
Biphenyl compounds useful as muscarinic receptor antagonists
Wherein a, b, c, d, m, n, p, s, t, w, ar1, r1, r2, r3, r4, r6, r7, and r8 are as defined in the specification. The compounds of formula i are muscarinic receptor antagonists.


Popular terms: [SEARCH]

Antagonist topics: Antagonist, Recurrence, Proliferative Disorder, Proliferative, Antibodies, Progesterone, Dicyclomine, Scopolamine, Extracellular, Pharmaceutically Acceptable Salt, Metalloprotein, Nucleic Acids, Polynucleotide, Nucleic Acid, Monoclonal

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antagonist for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antagonist with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4213

3904

449497 - 0 - 82